F
Fei Huang
Researcher at Bristol-Myers Squibb
Publications - 34
Citations - 2045
Fei Huang is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Receptor tyrosine kinase & Cancer. The author has an hindex of 17, co-authored 34 publications receiving 1952 citations.
Papers
More filters
Journal ArticleDOI
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts.
Yudi Pawitan,Judith Bjöhle,Lukas C. Amler,Anna-Lena Borg,Suzanne Egyhazi,Per Hall,Xia Han,Lars Holmberg,Fei Huang,Sigrid Klaar,Edison T. Liu,Lance D. Miller,Hans Nordgren,Alexander Ploner,Kerstin Sandelin,Peter M. Shaw,Johanna Smeds,Lambert Skoog,Sara Wedrén,Jonas Bergh +19 more
TL;DR: A subset of 64 genes was found to give an optimal separation of patients with good and poor outcomes, and the signature associated with prognosis and impact of adjuvant therapies was identified.
Journal ArticleDOI
Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection
Fei Huang,Karen A. Reeves,Xia Han,Craig R. Fairchild,Suso Platero,Tai W. Wong,Francis Y.F. Lee,Peter E. Shaw,Edwin A. Clark +8 more
TL;DR: It is implicate that dasatinib may represent a valuable treatment option in this difficult-to-treat population of patients with resistance or intolerance to prior therapy and to test this hypothesis, clinical studies are under way to determine the activity of d asatinib in these patients.
Journal ArticleDOI
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Fei Huang,Ann Greer,Warren Hurlburt,Xia Han,Rameh Hafezi,Gayle M. Wittenberg,Gayle M. Wittenberg,Karen A. Reeves,Jiwen Chen,Douglas Michael Robinson,Aixin Li,Francis Y. Lee,Marco M. Gottardis,Edwin A. Clark,Lee J. Helman,Ricardo M. Attar,Ashok Dongre,Joan M. Carboni +17 more
TL;DR: A strategy for testing combinations of IGF-IR inhibitors with other targeted therapies in clinical studies to achieve improved patient outcomes is provided and further exploration of mechanisms for intrinsic and acquired drug resistance by these preclinical studies may lead to more rationally designed drugs that target multiple pathways for enhanced antitumor efficacy.
Journal ArticleDOI
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy
Beate C. Litzenburger,Chad J. Creighton,Anna Tsimelzon,Bonita Tak-Yee Chan,Susan G. Hilsenbeck,Tao Wang,Joan M. Carboni,Marco M. Gottardis,Fei Huang,Jenny C. Chang,Michael T. Lewis,Mothaffar F. Rimawi,Adrian V. Lee,Adrian V. Lee +13 more
TL;DR: The IGF signature was present in triple-negative breast cancers and TNBC cell lines, which were especially sensitive to BMS-754807, and sensitivity was significantly correlated to the expression of the IGF gene signature.
Journal ArticleDOI
Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model
Fei Huang,Warren Hurlburt,Ann Greer,Karen A. Reeves,Stephen Hillerman,Han Chang,Joseph Fargnoli,Friedrich Graf Finckenstein,Marco M. Gottardis,Joan M. Carboni +9 more
TL;DR: This is the first study to define and compare acquired resistance mechanisms for IGF-IR/IR small-molecule inhibitor versus anti-IGF-IR antibody and provides insights into the differential acquired Resistance mechanisms.